Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
California congressman urges closer consultation with tribes on offshore wind
A congressman who represents California’s north coast has sent a letter to federal regulators asking2024-05-21Masterful meals: Masterchef 2014 Champion Ping Coombes's nasi goreng with sambal belacan
Roast pheasant, chocolate roulade and this sublime soup... a new book features spectacular dishes fr2024-05-21Rustle these up with Rosemary: Sun
In her new book, chef Rosemary Shrager guides you through tried and tested recipes that she vows wil2024-05-21Rustle these up with Rosemary: My traditional steak and kidney pie
In her new book, chef Rosemary Shrager guides you through tried and tested recipes that she vows wil2024-05-21Messi in and Dybala out in Argentina squad for pre
BUENOS AIRES, Argentina (AP) — Lionel Messi is in and Paulo Dybala is out of Argentina’s squad for f2024-05-21Dog severely burned and abandoned by owner in San Bernardino
CBS News Los Angeles Live2024-05-21
atest comment